N Andjelic Dekic

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
1106 Background: Inflammatory breast carcinoma (IBC) is rare but aggressive form of breast cancer. Up to 38% of IBC are HER-2+. According to literature, complete remission (CR) can be achived in more than 50% of patients with combinatination of chemotherapy and trastuzumab. However, trastuzumab is still not available in all countries. The aim of this study(More)
  • 1